Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial

Bibliographic Details
Title: Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial
Authors: Maria Isabel Lopes, Leticia P Bonjorno, Marcela C Giannini, Natalia B Amaral, Pamella Indira Menezes, Saulo Musse Dib, Samara Libich Gigante, Maira N Benatti, Uebe C Rezek, Laerte L Emrich-Filho, Betania A A Sousa, Sergio C L Almeida, Rodrigo Luppino Assad, Flavio P Veras, Ayda Schneider, Tamara S Rodrigues, Luiz O S Leiria, Larissa D Cunha, Jose C Alves-Filho, Thiago M Cunha, Eurico Arruda, Carlos H Miranda, Antonio Pazin-Filho, Maria Auxiliadora-Martins, Marcos C Borges, Benedito A L Fonseca, Valdes R Bollela, Cristina M Del-Ben, Fernando Q Cunha, Dario S Zamboni, Rodrigo C Santana, Fernando C Vilar, Paulo Louzada-Junior, Rene D R Oliveira
Source: RMD Open, Vol 7, Iss 1 (2021)
Publisher Information: BMJ Publishing Group, 2021.
Publication Year: 2021
Collection: LCC:Medicine
Subject Terms: Medicine
More Details: Objective To evaluate whether the addition of colchicine to standard treatment for COVID-19 results in better outcomes.Design We present the results of a randomised, double-blinded, placebo-controlled clinical trial of colchicine for the treatment of moderate to severe COVID-19, with 75 patients allocated 1:1 from 11 April to 30 August 2020. Colchicine regimen was 0.5 mg thrice daily for 5 days, then 0.5 mg twice daily for 5 days. The primary endpoints were the need for supplemental oxygen, time of hospitalisation, need for admission and length of stay in intensive care unit and death rate.Results Seventy-two patients (36 for placebo and 36 for colchicine) completed the study. Median (and IQR) time of need for supplemental oxygen was 4.0 (2.0–6.0) days for the colchicine group and 6.5 (4.0–9.0) days for the placebo group (p
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2056-5933
Relation: https://rmdopen.bmj.com/content/7/1/e001455.full; https://doaj.org/toc/2056-5933
DOI: 10.1136/rmdopen-2020-001455
Access URL: https://doaj.org/article/4129e67bbc1e4c5388c06c260b55f530
Accession Number: edsdoj.4129e67bbc1e4c5388c06c260b55f530
Database: Directory of Open Access Journals
More Details
ISSN:20565933
DOI:10.1136/rmdopen-2020-001455
Published in:RMD Open
Language:English